In a large outcome study (MERLIN-TIMI 36) in 6,560 patients with UA/ NSTEMI ACS, there was no difference between Ranexa and placebo in the risk of all-cause mortality (relative risk ranolazine: placebo 0.99), sudden cardiac death (relative risk ranolazine: placebo 0.87), or the frequency of symptomatic documented arrhythmias (3.0% versus 3.1%).